drugset
drugset / Trial / NCT04873752

A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy

NCT04873752 ↗

Phase 1/2 Completed 6 enrolled Rohto Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

UDI-001 is administered to pediatric patients with cerebral palsy attributed to periventricular leukomalacia (PVL) multiple times to investigate its safety and efficacy.

Timeline

Start
2021-06-02
Primary completion
2023-07-12
Completion
2024-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject UDI-001 Cell therapy 2.5 cells/kg Intravenous

Indications

cerebral palsy periventricular leukomalacia